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bstract
Aspartame is a non-nutritive sweetener that is used predominantly in various ‘diet’ and ‘low-calorie’ products, such as beverages,
nstant breakfasts, desserts, breath mints, sugar-free chewing gum, vitamins, and pharmaceuticals, consumed by millions of people
ho are attempting weight loss, young adults and diabetic persons. On a weight basis, the metabolism of aspartame generates
pproximately 50% phenylalanine, 40% aspartic acid and 10% methanol. The detailed mechanisms of the effects of aspartame
n the electrophysiological response are still unclear; therefore, this study was designed to clarify whether longer-term aspartame
onsumption has any effect on the electrophysiological response in Wistar albino rats. The oral administration of aspartame in
 safe dose of 40 mg/kg bodyweight/day (as recommended by EFSA, 2012) was tested in Wistar albino rats for a longer period
90 days). Electrophysiological responses, including heart rate variability (HRV) and electroencephalogram (EEG) pattern, were
ssessed in a folate-deficient animal model along with control animals using BIOPAC and EEG equipment (model RMS EEG–24
rain new-plus: RMS – Recorder and Medicare systems). In this study, the folate-deficient animal model was used to mimic human
ethanol metabolism in rats. After 90 days of aspartame treatment, a significant alteration was observable in the time domain [Mean
R (ms) SDNN (ms) RMSSD (ms) PNN50 (%)] and the frequency domain [LF, HF, and LF/HF ratio] with significantly impaired
requency and amplitude of the fronto-parietal and occipital EEG waves at p  ≤  0.05. The results of this study clearly indicate that
he oral consumption of aspartame reduced HRV, with sympathetic dominance and loss of vagal tone, and altered sympathovagal
ctivity along with impairment of learning and memory, showing an additional effect on health within this study duration. The
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1.  Introduction
Cardiovascular diseases remain the principal cause
of death in both developed and developing countries,
accounting for approximately 20% of all deaths world-
wide annually. Aspartame (anon-nutritive sweetener) is
added to a variety of foodstuffs, offering an alternative
sweetening choice to diabetics, dieters, and others who
must limit sugar intake. It is consumed by millions of
people in numerous products such as beverages, instant
breakfasts, desserts, breath mints, sugar-free chewing
gum, vitamins, and pharmaceuticals [1]. Aspartame is
completely metabolized in the gut and absorbed as the
two amino acids aspartic acid (40%) and phenylalanine
(50%) along with methanol (10%) [2]. After aspar-
tame consumption, the concentrations of its metabolites
are increased in the blood [3]. Aspartame is unstable
under conditions of prolonged heating and is inappro-
priate for use in cooking and baking [4]. Aspartame
also decomposes in liquids during prolonged storage.
It is known that the rat constitutes an important model
for cardio-vascular physiologic research, and ECG-
based studies have long been conducted in this animal
model. Cardiac activation is an electrical propagation
that results in a measurable change in potential differ-
ence on the surface of the body of the subject. The
resulting amplified and filtered electrical signal is the
electrocardiogram and is widely used to measure the
heart rate and heart rate variability [5]. The baseline
variability of the heart rate (beat to beat interval) is deter-
mined on many scales; on the shortest scale, the time
between each heartbeat is irregular. These short-term
oscillations reflect changes in the sympathovagal bal-
ance [5]. Our hypothesis was that methanol, a metabolite
of aspartame, might cause oxidative stress in the car-
diovascular centres in the brain stem and/or sympathetic
centres in the hypothalamus [6]. These mechanisms may
affect cardiac function in experimental animals. The
experimental and epidemiological data currently avail-
able to evaluate the above toxigenic risks of aspartame
are insufficient and often unreliable due to the inade-
quate planning and conduct of previous experiments.
Recently, based on previous studies, the ability of aspar-
tame and its metabolites to alter the oxidative status of
the cells via reactive oxygen species (ROS) generation
and the modulation of intracellular antioxidant enzyme
levels were investigated. Oral aspartame consumption
at 75 mg/(kg bw/day) has been found to cause oxidative
stress in the brain and liver [6,7], and oral aspartame con-
sumption at 40 mg/(kg bw/day) has been found to cause
oxidative stress in the brain [8], liver and kidney [9],
and immune organs [10] and to alter immune responseversity for Science 10 (2016) 505–512
[11]. The inadequacy of past studies, combined with
the general limited knowledge about the safety/potential
toxigenic effects of substances widely present in
the industrialized diet, motivated the design of this
experiment.
Heart rate variability (HRV) [12] is considered to
be a non-invasive measure of autonomic nervous sys-
tem activity. Despite the importance of HRV as a
reproducible marker of sympathetic–parasympathetic
balance, the studies related to HRV in aspartame-treated
animal are very few. Little is known about the effects of
aspartame on electrophysiological response (HRV and
EEG). The detailed mechanisms of the effects of aspar-
tame remain unclear; the purpose of the current study is
to clarify whether longer-term aspartame consumption
has any effect on the electrophysiological response of
Wistar albino rats.
2.  Material  and  method
2.1.  Chemicals
Pure aspartame powder and methotrexate was pur-
chased from Sigma–Aldrich chemical, St. Louis, USA,
and all other chemicals used were of analytical grade
and obtained from Sisco Research Laboratory, Mumbai,
India.
2.2.  Animal  model
Animal experiments were conducted after obtaining
clearance from the Institutional Animal Ethical Commit-
tee (IAEC No: 01/21/2014) and the Committee for the
Purpose of Control and Supervision of Experiments on
Animals (CPCSEA). The animal studies were approved
by the appropriate ethics committee and have therefore
been performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki and its later
amendments. It should also be stated clearly in the text
that all persons gave their informed consent prior to their
inclusion in the study. The experimental animals were
healthy, inbred adult male Wistar albino rats, weighing
approximately 200–220 g. The animals were maintained
under standard laboratory conditions and were allowed
food and water ad libitum (standard rat feed pellets sup-
plied by M/s. Hindustan Lever Ltd., India). Animals of
the aspartame-treated groups were daily administered
aspartame (40 mg/kg bw/day) [13,14] dissolved in nor-days. All of the rats were housed under conditions of
controlled temperature (26 ±  2 ◦C) with 12-h light and
12-h dark exposure.
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.3.  Folate-deﬁcient  model  and  treatment
Animals were randomly divided into four groups,
ach consisting of six animals. Group 1 included the
ontrol animals, which were administered normal saline
rally (by means of gavage needle) throughout the
xperimental protocol. Group 3 consisted of control
nimals treated with aspartame orally for 90 days
40 mg/kg bw/day). In this study, animals fed a folate-
eficient diet were used to mimic the human methanol
etabolism, as human beings have very low hepatic
olate content [15]. In the methanol metabolism, the
onversion of formate to carbon dioxide is folate depend-
nt. Hence, in the case of a deficiency of folic acid,
he methanol metabolism can take an alternate path-
ay (the microsomal pathway) [16]. To simulate this
rocess, rats were made folate deficient by feeding
hem a special dietary regime for 37 days, after which
ethotrexate (MTX) in sterile saline was administered
very other day for two weeks [17] before euthanasia.
TX folate deficiency was confirmed by estimating the
rinary excretion of formaminoglutamic acid (FIGLU)
18] prior to the experiment. Rats on a folate-deficient
iet excreted an average of 90–100 mg FIGLU/kg
ody weight/day (range 25–125), while animals on the
ontrol diet excreted an average of 0.29 mg/kg body
eight/day (range 0.15–0.55). These folate-deficient
nimals showed a significant increase in FIGLU excre-
ion compared to the control animals (P  < 0.05). The
olate-deficient animals were further divided into two
roups. Group 2 consisted of animals fed a folate-
eficient, while Group 4 consisted of animals fed a
olate-deficient diet and treated with aspartame orally
or 90 days (40 mg/kg bw/day).
.4.  Experimental  Groups
Group 1 Control animals.
Group 2 Folate-deficient diet fed animals.
Group 3 Control animals treated with aspartame
40 mg/kg bw) orally for 90 days.
Group 4 Folate-deficient diet fed animals treated with
spartame (40 mg/kg bw) orally for 90 days.
.5.  Experimental  procedure
.5.1.  Measurement  of  heart  rate  variability  (HRV)
Different approaches based on spectral and timeomain analysis were used to evaluate the cardiac rhythm
egulatory response to aspartame. HRV monitoring using
he radio-telemetric system has been described previ-
usly [19,20]. The time intervals between adjusted Rversity for Science 10 (2016) 505–512 507
waves in the electrocardiography channel (RR) were
obtained on a beat-to-beat basis using the Dataquest
A.R.T. analysis software (version 2.20; Data Sciences
International, USA). Errors resulting from the R-wave
detector were eliminated using the following criteria
to obtain normal-to-normal (NN) intervals. The most
commonly used approaches to the analysis of heart rate
variability are time domain (TD) and frequency domain
(FD) analyses [21]. In time domain analysis, the inter-
vals between normal N-N waves are measured over the
period of the recording. The NN intervals are used to
determine the SD of the NN intervals (SDNN) and the
root mean square of successive differences of adjacent
NN intervals (RMSSD). Simple descriptive statistics are
used to obtain measures of HRV in this method. Fre-
quency domain methods are expressed in the form of a
spectral density function that depicts spectral power as
a function of frequency [22]. High frequency is solely
mediated by changing levels of vagal activity [23,24],
whereas low frequency is mediated by both sympathetic
and vagal activity.
2.5.2. Electroencephalogram  (EEG)  measurement
Electrodes were implanted in all of the animals after
the last session of aspartame treatment. In brief, animals
were anesthetized with ketamine/xylazine (90/15 mg/kg,
i.p.). The toe pinch method was used once every 5 min
to check the responsiveness after the administration of
anaesthetic agent, after which the animal was fixed in
a stereotaxic frame. After aseptic cleaning procedures,
a small incision was made in the skin and a recording
electrode fixed on the surface of the scalp. The electrode
was placed on the scalp and glued with dental acrylic
resin, and the incision was closed and sutured, expos-
ing the electrode. Post-operative care was performed
according to ethical guidelines with the administration
of saline and to prevent fluid loss during incision and
of antibiotic to prevent sepsis. After recovery, the elec-
trodes were connected to the EEG equipment (using
model RMS EEG–24 brain new-plus: RMS – Recorder
and Medicare systems). The EEG activity was recorded
for approximately 10 min in anesthetized rats. Signals
were filtered between 1 and 70 Hz. Recordings were
analyzed by RMS EEG–24 Super sec version 1.1 and
expressed in terms of amplitude (v) and frequency
(Hz). All experiments were performed at the same time
of day (10:00–12:00 am) to eliminate variation due to
circadian rhythms.
2.6.  Statistical  analysis
Data are expressed as the mean ±  standard devia-
tion (SD). All data were analyzed using the SPSS for
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Table 1
Aspartame on heart rate variability (HRV).
Parameter Control FD Control +ASP FD + ASP
Mean NN interval 280 ± 25 295 ± 30 420 ± 13*a,*b 428 ± 20*a,*b
Frequency domain analysis
Total spectral power (TSP) ms2 7.8 ± 0.94 6.84 ± 0.85 3.45 ± 0.52*a,*b 3.27 ± 0.60*a,*b
Lower frequency (LF) ms2 0.62 ± 0.15 0.78 ± 0.19 1.54 ± 0.30*a,*b 1.70 ± 0.28*a,*b
Higher frequency (HF) ms2 5.50 ± 0.90 4.84 ± 0.73 2.72 ± 0.54*a,*b 2.30 ± 0.45*a,*b
LF/HF ratio 0.23 ± 0.03 0.19 ± 0.02 0.12 ± 0.02*a,*b 0.10 ± 0.03*a,*b
Time domain analysis
SDNN (ms) 4.8 ± 0.85 4.20 ± 0.70 1.83 ± 0.54*a,*b 1.71 ± 0.42*a,*b
RMSSD (ms) 3.24 ± 0.52 2.30 ± 0.60 0.82 ± 0.23*a,*b 0.64 ± 0.28*a,*b
PNN50 2.17 ± 0.44 1.92 ± 0.35 0.90 ± 0.15*a,*b 0.78 ± 0.13*a,*b
Effect of aspartame on heart rate variability (HRV). Each value represents mean ± SD. Significance at *p < 0.05, *a – compared with control, *b –
compared with folate-deficient rats (FD). FD: folate deficient, ASP: aspartame. SDNN: Standard deviation of the NN intervals, RMSSD: Square
50, Nu
tal numroot of the mean squared differences of successive NN intervals, NN
50 ms, and pNN50, the proportion derived by dividing NN50 by the to
Windows statistical package (version 20.0, SPSS
Institute Inc., Cary, North Carolina. The statistical sig-
nificance among the four different groups was analyzed
using the one-way ANOVA test followed by Tukey’s
multiple comparison tests, and the significance level was
fixed at p  < 0.05.
3.  Results
3.1.  Effect  of  aspartame  on  mean  RR  interval
The results are summarized in (Table 1) as the
mean ±  SD. The RR interval was not significantly altered
in folate-deficient animals compared to control ani-
mals. However, both control and folate-deficient animals
treated with aspartame for 90 days showed a signifi-
cant increase in RR interval compared to control and
folate-deficient animals not treated with aspartame.
3.2.  Effect  of  aspartame  on  frequency  domain
analysis
The data are summarized in (Table 1) as the mean
±SD. The total spectral power, lower frequency, higher
frequency and LF/HF ratio of folate-deficient animals
were similar to the control animals. However, both the
control and the folate-deficient animals treated with
aspartame for 90 days showed significant decreases in
total spectral power and higher frequency and significant
increases in lower frequency and LF/HF ratio compared
to controls and folate-deficient animals not treated with
aspartame.mber of interval differences of successive NN intervals greater than
ber of NN intervals.
3.3.  Effect  of  aspartame  on  time  domain  analysis
The results are summarized in (Table 1) as the
mean ±  SD. The standard deviation of the NN intervals
(SDNN), the square root of the mean squared differences
of successive NN intervals (RMSSD), and the propor-
tion derived by dividing NN50 by the total number of
NN intervals (PNN50) of folate-deficient animals were
similar to the corresponding values for the control ani-
mals. However, both control and folate-deficient animals
treated with aspartame for 90 days showed significant
decreases in SDNN, RMSSD, and PNN50 compared
to control and folate-deficient animals not treated with
aspartame.
3.4.  Effect  of  aspartame  on  EEG  analysis
parameters that  reﬂect  learning  and  memory
The results are summarized in (Fig. 1a–f) as the
mean ±  SD. The amplitude and frequency of EEG
waves in the fronto-temporal and occipital lobes of
folate-deficient animals were similar to the control ani-
mals. However, both control and folate-deficient animals
treated with aspartame for 90 days showed a significant
increase in amplitude and decrease in frequency com-
pared to control and folate-deficient animals not treated
with aspartame.
4.  DiscussionLaboratory animals have been used in research on
an ongoing basis, and non-invasive methods are being
increasingly implemented in cardiac autonomic regu-
lation, including heart rate variability analysis (HRV).
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xperimental studies on human cardiovascular function
re obviously limited for safety reasons. In most animal
tudies, non-parametric methods (time and frequency
omain) are used normally. In this study, we showed
he HRV and EEG response to aspartame metabolites in
spartame-fed rats thoroughly habituated to the labora-
ory conditions. We developed a folate-deficient model
o mimic the human methanol metabolism in rats. The
ime interval between heartbeats is not constant, and the
ariability that occurs is due to a variety of physiological and frequency) of both the fronto-parietal and occipital regions. Each
ntrol animals, *b – compared with folate-deficient (FD) animals. FD:
processes that affect the heart rate at different frequen-
cies. The measured tachogram of HRV is a reflection
of all of the different interacting phenomena. The PSA
of HRV divides the overall variability into separate fre-
quencies and thereby enables the identification of the
activity of the various affecting components [25]. This
non-invasive technique has attracted considerable inter-
est in both cardiology [26] and neurology [27]. Time-
and frequency-domain HRV parameters were obtained
and analyzed simultaneously. SDNN and RMSSD are
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time-domain indices of HRV, reflecting parasympa-
thetic modulation of the RR interval. In this study,
these indices were reduced in the aspartame-treated ani-
mals compared to the untreated animals. The reduction
of SDNN, RMSSD and PNN50 in aspartame-treated
animals clearly shows that cardiac parasympathetic mod-
ulation is reduced in these animals. Heart rate variability
(HRV) has attracted considerable interest as a non-
invasive index of frequency-specific modulation of the
SA node by the autonomic nervous system. LF power
is contributed by changes in sympathetic and parasym-
pathetic activity to the heart [26]. LF quantifies the
baroreflex modulation of RR intervals, and HF quan-
tifies baroreflex-mediated changes in RR intervals at the
respiratory frequency [24]. This study showed that LF
was significantly increased, HF was reduced, and the
LF/HF ratio was significantly decreased in aspartame-
treated animals. Total power (TP), an index of overall
HRV, was also reduced in our aspartame-treated animals.
An increase in sympathetic activity can also lead to the
formation of oxidative by-products [28]. Oxidative stress
results from an oxidant–antioxidant imbalance [29] and
plays a role in the pathogenesis of many diseases [30].
Reactive oxygen species (ROS) play a role in elevating
central and peripheral sympathetic activity by increas-
ing nitric oxide production [31]. Our previous study
showed that aspartame acts as a chemical stressor, alters
the oxidative–antioxidative balance [10,11], increases
oxidative stress, and depresses HRV [32]. When a person
is exposed to a stressor, the autonomic nervous (ANS)
system is triggered: the parasympathetic nervous sys-
tem is suppressed, and the sympathetic nervous system
is activated [24]. This process results in the secretion
of the hormones epinephrine and norepinephrine into
the bloodstream and changes in heart rate (HR) and
heart rate variability (HRV) [33]. An increase in HR,
generally considered to result from a shift of the sym-
pathovagal balance towards the sympathetic nervous
system, was associated with a modest increase in the
LF/HF ratio, which, on the contrary, suggests sympa-
thetic gain. Tight links seem to exist between time-
and frequency-domain HRV measures, as suggested by
the high association between RMSSD and HF-spectral
power or SDNN and TP, indicating the consistency of
the obtained data. In rats, sympathetic efferents are dom-
inant regulatory components that control the heart rate
[34]. Their HRV resembles its human counterpart, with
two principal components: the LF and HF [35]. Reduced
HRV is an independent indicator of adverse prognosis in
cardiac disorder [36,37].
Normal thinking and decision making with higher
cognitive abilities are mainly associated with theversity for Science 10 (2016) 505–512
prefrontal cortex [38] and involve the activation and
transmission of signals in the neurons of the prefrontal
cortex. They also have connections with other regions of
the brain that regulate cognitive, emotion and memory
functions. In addition to the prefrontal cortex, the pari-
etal and occipital cortices also play a role by transferring
the highly processed visuospatial information and ocu-
lomotor attention guidance to the dorsolateral prefrontal
cortex [39]. Furthermore, in addition to visual functions,
the occipital cortex is involved in non-visual functions
such as spatial recognition memory [40]. In particu-
lar, the medial extrastriate visual cortex is involved in
mediating the memory of visual object information [41].
Hence, all of the information and signals are conducted
to the frontal cortex for further processing and analy-
sis by different pathways and connections. The activity
of these brain areas can be recorded cortically by EEG
[42]. The occipital cortex (medial extrastriate visual cor-
tex) is involved in visual recognition memory [43]. In
this study, EEG waves (amplitude and frequency) were
altered in both the fronto-parietal and occipital region in
aspartame-treated animals, which might affect learning
and memory in rats.
Aspartame has previously been reported to affect the
brain through the elevated release of ROS and RNS
[6,44]. It is postulated that the consumption of aspartame
might potentially perturb the amount of biogenic amines
in brain via the aspartame-induced increase in phenyl-
alanine and tyrosine [45]. Na+/K+-ATPase is inhibited
by oxygen reactive substances, as demonstrated in the
brain [46]. The administration of aspartame alone or, in
the presence of mild systemic inflammatory response,
the intraperitoneal (i.p.) administration of lipopolysac-
charide increases oxidative stress and inflammation in
the brain but not in the liver [47]. Yokogoshi and Wurt-
man [48] reported that brain norepinephrine levels were
increased in rats 2 h after gavage with a single dose of
aspartame (200 mg/kg bw) compared with saline con-
trols. This current finding on aspartame is also consistent
with previous reports.
5.  Conclusion
The results showed that heart rate variability was
markedly decreased in aspartame-treated rats. Our pre-
vious study showed that aspartame acts as a chemical
stressor and impairs the oxidative–antioxidative balance,
which may be associated with the reduced HRV, sympa-
thetic dominance and loss of vagal tone appearing in this
study. The loss of protective vagal tone would explain
the increased vulnerability to cardiovascular disease.
An increasing number of physical illnesses also appear
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